Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria
Sponsor: Ra Pharmaceuticals
This PHASE2 trial investigates Paroxysmal Nocturnal Hemoglobinuria (PNH) and is currently completed. Ra Pharmaceuticals leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Oct 2018 — Apr 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ra Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .